BridgeBio Pharma Inc (BBIO)
24.72
-0.26
(-1.02%)
USD |
NASDAQ |
Apr 19, 16:00
24.76
+0.04
(+0.16%)
After-Hours: 18:08
BridgeBio Pharma Debt to Equity Ratio: -1.275 for Dec. 31, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| December 31, 2023 | -1.275 |
| September 30, 2023 | -1.425 |
| June 30, 2023 | -1.262 |
| March 31, 2023 | -1.398 |
| December 31, 2022 | -1.361 |
| September 30, 2022 | -1.492 |
| June 30, 2022 | -1.651 |
| March 31, 2022 | -1.641 |
| December 31, 2021 | -1.958 |
| Date | Value |
|---|---|
| September 30, 2021 | -1.85 |
| June 30, 2021 | -2.959 |
| March 31, 2021 | -3.453 |
| December 31, 2020 | 8.243 |
| September 30, 2020 | 2.882 |
| June 30, 2020 | 1.756 |
| March 31, 2020 | 1.212 |
| December 31, 2019 | 0.2247 |
| September 30, 2019 | 0.1632 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-3.453
Minimum
Mar 2021
8.243
Maximum
Dec 2020
-0.4025
Average
-1.379
Median
Debt to Equity Ratio Benchmarks
| Pfizer Inc | 0.7959 |
| Alnylam Pharmaceuticals Inc | -4.626 |
| Ardelyx Inc | 0.2987 |
| Regenxbio Inc | 0.00 |
| IDEAYA Biosciences Inc | 0.00 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 546.38M |
| Total Liabilities (Quarterly) | 1.889B |
| Shareholders Equity (Quarterly) | -1.354B |
| Current Ratio | 3.320 |
| Net Debt Paydown Yield | -0.08% |